Eric H. Chan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and(More)
  • 1